Table 4 |
|||||||
|
Lipid and Inflammatory Measures at Week 0 and Week 16 |
|||||||
|
Measurement† |
Week |
MD Group Mean ± SD |
Within Group Δ p-value |
Week |
FB Group Mean ± SD |
Within Group Δ p-value |
Between Group Δ p-value |
|
|
|||||||
|
Total Cholesterol |
0 (n = 39) |
191.2 ± 39.5 |
p = 0.841 |
0 (n = 40) |
187.5 ± 43.0 |
p = 0.687 |
p = 0.409 |
|
(mg/dl) |
16 (n = 25) |
181.3 ± 40.4 |
16 (n = 20) |
184.9 ± 45.9 |
|||
|
HDL |
0 (n = 39) |
52.0 ± 16.0 |
p = 0.843 |
0 (n = 40) |
51.8 ± 18.0 |
p = 0.261 |
p = 0.62 |
|
(mg/dl) |
16 (n = 25) |
51.6 ± 11.3 |
16 (n = 20) |
48.2 ± 11.3 |
|||
|
LDL |
0 (n = 39) |
117.3 ± 31.8 |
p = 0.253 |
0 (n = 40) |
108.8 ± 32.0 |
p = 0.779 |
p = 0.396 |
|
(mg/dl) |
16 (n = 25) |
111.4 ± 34.4 |
16 (n = 19) |
110.7 ± 37.6 |
|||
|
VLDL |
0 (n = 38) |
21.9 ± 13.0 |
p = 0.026 |
0 (n = 37) |
27.9 ± 17.9 |
p = 0.01 |
p = 0.652 |
|
(mg/dl) |
16 (n = 24) |
17.5 ± 9.8 |
16 (n = 20) |
26.1 ± 16.4 |
|||
|
Triglycerides |
0 (n = 39) |
109.2 ± 63.7 |
p = 0.061 |
0 (n = 40) |
134.7 ± 86.8 |
p = 0.009 |
p = 0.502 |
|
(mg/dl) |
16 (n = 25) |
91.8 ± 52.7 |
16 (n = 20) |
130.4 ± 81.6 |
|||
|
CRP |
0 (n = 38) |
5.7 ± 4.8 |
p = 0.200 |
0 (n = 39) |
7.1 ± 9.4 |
p = 0.018 |
p = 0.45 |
|
(mg/L) |
16 (n = 25) |
3.6 ± 2.9 |
16 (n = 20) |
4.3 ± 4.7 |
|||
|
ULP |
0 (n = 44) |
6.1 ± 2.2 |
p = 0.684 |
0 (n = 44) |
5.5 ± 1.7 |
p = 0.538 |
p = 0.973 |
|
(micromol/g creatinine) |
16 (n = 27) |
6.2 ± 2.2 |
16 (n = 20) |
5.3 ± 2.4 |
|||
|
|
|||||||
|
Δ = Change from baseline to 16 weeks. † = Secondary outcomes. |
|||||||
|
Davis et al. Nutrition Journal 2010 9:11 doi:10.1186/1475-2891-9-11 |
|||||||
